# Refuge Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/refuge-biotechnologies

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.refugebiotech.com
- Total disclosed funding: $25M
- Latest round: Series B (May 2, 2018)
- Investors on record: 8

## About

Refuge Biotechnologies, Inc. develops advanced biopharmaceuticals and genetic engineering tools, addressing critical healthcare and agricultural challenges with innovative solutions tailored for diverse markets.Founded in 2015 and headquartered in Menlo Park, US, Refuge Biotechnologies specializes in biotechnological advancements. The company has raised a total of USD 25.00 mn through its most recent funding round, Series B, which included investors such as 3E Bioventures Capital and Sequoia Capital. The company has successfully completed 2 deals to date, reflecting its growth trajectory under the leadership of CEO Bing Wang, while founder David Parkinson has a history of entrepreneurial ventures.Refuge Biotech specializes in developing innovative biotechnological solutions aimed at addressing critical challenges in healthcare and agriculture. The core product offerings comprise advanced biopharmaceuticals and genetic engineering tools designed to enhance treatment efficacy for various diseases and improve crop resilience in adverse environmental conditions. These products are tailored to meet the needs of healthcare providers, farmers, and research institutions. With a focus on precision medicine and sustainable agricultural practices, the company serves a diverse clientele across key geographical markets, including North America, Europe, and parts of Asia. Through partnerships and collaborations with leading organizations in the biotech sector, Refuge Biotech aims to deliver solutions that facilitate improved patient outcomes and agricultural productivity.Refuge Biotech generates revenue through a combination of direct sales and strategic partnerships, primarily engaging in B2B transactions with healthcare providers and agricultural enterprises. The company's revenue model includes subscriptions for access to proprietary technology platforms, licensing agreements for its biopharmaceutical products, and direct sales of its genetically engineered solutions. Transactions often occur through long-term contracts that ensure a steady stream of income, with clients committing to annual purchases based on projected needs. The pricing structure is aligned with industry standards, reflecting the value of its flagship biopharmaceuticals and agricultural products. By maintaining robust relationships with its client base, Refuge Biotech effectively positions itself to capitalize on emerging opportunities in the biotech landscape.Refuge Biotechnologies is actively pursuing the development of new biopharmaceutical products, with plans to launch several innovative treatments by the end of 2024. The company aims to expand its market presence in Asia and Europe, targeting specific regions by the third quarter of 2025. The recent funding from the Series B round will be directed toward bolstering R&D efforts and scaling operations to support these initiatives. Additionally, 6 Dimensions Capital has exited its stake in the company, which may influence future strategic partnerships.

## Funding rounds

- Series B, May 2, 2018, $25M — Hong Shan, 3SBio Inc., 6 Dimensions Capital, DHVC, 3E Bioventures Capital, Sangel Capital, ShangBay Capital, Oceanpine Capital

## Investors

- Hong Shan — Series B
- 3SBio Inc. — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B
- DHVC (https://capitalatlas.ai/funds/dhvc) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series B
- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series B
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series B